Skip to content
Trident Lifeline logo

Trident Lifeline

543616 BSE
₹418.00

Close ·

P/E
23.58
View as Markdown
MCP
Close 4 Nov 2026 ₹418.00 +112.05 +36.6% 1Y
Start ₹305.95

Key Fundamentals

SMEPharmaceuticals & BiotechnologyHealthcare

Price-based figures at the close · EPS basis: Consolidated · TTM

ROCE
21.10%
Debt to Equity
0.73
EPS (TTM)
₹17.73
Book Value
₹95.52
Market Cap
—
P/E (TTM)
23.58
P/B
4.38
ROE
22.60%
Dividend Yield
0.12%
EBITDA
₹38.60 Cr
52W High
₹442.00
52W Low
₹229.95

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

57 Good

Data confidence 98/100

Category scores

Quality
51
Average
Returns, margins, earnings quality 22% weight
Valuation
43
Weak
Cheap vs sector & own history 24% weight
Growth
97
Strong
Sales & profit trajectory 9% weight
Financial Health
46
Average
Solvency, leverage, coverage 9% weight
Momentum
98
Strong
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company is expected to give good quarter

Weaknesses

3
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has high debtors of 209 days.
  • Promoter holding has decreased over last 3 years: -7.58%

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish2710
OscillatorsBearish270
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
58.56
Neutral
MACD (12,26,9)
16.30
Bearish
SMA (50)
356.22
Bullish
SMA (200)
286.10
Bullish

As of

Growth Rate

From the financial statements below. 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
3Y+59.15%
1Y+48.28%
TTM+65.75%

Net profit

Net profit growth by window
3Y+46.85%
1Y+90.00%
TTM+51.26%

Operating cash flow

Operating cash flow growth by window
3YTurned positive
1YTurned positive
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
3Y+2.96 pp
1Y+4.47 pp
TTM−3.35 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2022₹22.00 Cr
Mar 2023₹32.00 Cr
Mar 2024₹45.00 Cr
Mar 2025₹87.00 Cr
Mar 2026₹129 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2022₹4.00 Cr
Mar 2023₹6.00 Cr
Mar 2024₹6.00 Cr
Mar 2025₹10.00 Cr
Mar 2026₹19.00 Cr

Quarterly Results

₹ Cr
543616 quarterly results, ₹ crore
Particulars Mar 2023Jun 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
8.46
8.64
7.09
19.13
13.15
15.45
11.83
34.01
23.61
31.34
25.71
49.95
33.72
Expenses
6.52
6.88
5.66
16.77
10.66
11.4
7.76
25.47
18.44
24.48
20.62
38.96
25.2
Operating Profit
1.94
1.76
1.43
2.36
2.49
4.05
4.07
8.54
5.17
6.86
5.09
10.99
8.52
OPM %
22.93%
20.37%
20.17%
12.34%
18.94%
26.21%
34.4%
25.11%
21.9%
21.89%
19.8%
22%
25.27%
Other Income
0.64
0.33
0.25
1.47
1.15
0.54
0.56
1.87
1.35
1.67
4.63
1.62
0.57
Interest
0.15
0.1
0.15
0.37
0.49
0.5
0.55
1.55
1.13
0.99
1.24
0.77
0.86
Depreciation
0.12
0.13
0.19
0.39
0.54
0.16
0.61
2.74
1.46
0.91
2.46
1.23
1.62
PBT
2.31
1.86
1.34
3.07
2.61
3.93
3.47
6.12
3.93
6.63
6.02
10.61
6.61
Tax %
14.29%
24.73%
21.64%
46.91%
38.7%
28.5%
26.51%
−0.33%
29.26%
23.23%
22.76%
36%
23.3%
Net Profit
1.98
1.4
1.05
1.63
1.6
2.8
2.56
6.14
2.78
5.09
4.64
6.8
5.07
EPS (₹)
1.72
1.22
0.94
1.77
1.99
2.69
2.43
6.15
2.66
4.27
3.6
5.64
4.22

Profit & Loss

₹ Cr
543616 profit and loss, annual, ₹ crore
Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
22
32
45
87
129
141
Expenses
19
25
36
72
101
109
Operating Profit
3
6
8
15
28
31
OPM %
12%
20%
18%
17%
22%
22%
Other Income
1
1
2
8
10
8
Interest
0
0
1
4
5
4
Depreciation
0
0
1
5
6
6
PBT
3
7
9
14
27
30
Tax %
−32%
8%
32%
23%
29%
—
Net Profit
4
6
6
10
19
22
EPS (₹)
4.94
5.24
5.51
10.22
15.96
17.73
Div. Payout %
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
543616 balance sheet, annual, ₹ crore
Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
8
12
12
12
12
Reserves
−3
34
41
53
88
Borrowings
2
8
18
54
73
Other Liabilities
7
9
16
37
62
Total Liabilities
14
63
87
156
236
Fixed Assets
1
3
21
44
61
CWIP
0
5
4
2
18
Investments
0
3
4
11
8
Other Assets
12
51
58
99
149
Total Assets
14
63
87
156
236

Cash Flow

₹ Cr
543616 cash flow, annual, ₹ crore
Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
−19
2
−4
5
Investing
0
−10
−20
−14
−37
Financing
1
42
11
14
34
Net Cash Flow
0
14
−7
−4
2
Free Cash Flow
−1
−26
−16
−15
−29
CFO/EBITDA
−8
−294
56
4
43

Ratios

543616 financial ratios, annual
Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
83
139
110
116
209
Inventory Days
95
129
156
226
173
Days Payable
134
87
94
119
182
Cash Conversion Cycle
44
182
173
224
199
Working Capital Days
49
275
205
144
134
ROCE %
—
23%
15%
18%
21%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Trident Lifeline insights

61 extracted metrics across FY20–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 62.54%
  • Public 24.73%
  • Others 11.44%
  • FIIs 1.16%
  • DIIs 0.21%

6.93% of promoter holding pledged as of 14 Oct 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

  • Q1 FY27 concall · Aug 2026
    PPT
  • Concall · May 2026
    PPT
  • Q3 FY26 concall · Jan 2026
    PPT
  • Concall · Nov 2025
    PPT
  • Q1 FY26 concall · Jul 2025
    PPT

Frequently Asked Questions about Trident Lifeline

What does Trident Lifeline Ltd do?
Incorporated in 2014, Trident Lifeline Ltd manufactures and sells pharmaceuticals products
Where is Trident Lifeline Ltd (TLL) listed?
Trident Lifeline Ltd trades under code 543616 on the BSE.
Which sector does Trident Lifeline Ltd belong to?
Trident Lifeline Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Trident Lifeline Ltd?
Trident Lifeline Ltd trades at a PE ratio of 23.58 as of 4 Nov 2026, on earnings per share of ₹17.73, against a book value of ₹95.52 per share.
What is the 52-week high and low of Trident Lifeline Ltd?
Over the last 52 weeks Trident Lifeline Ltd has traded between ₹229.95 and ₹442 as of 4 Nov 2026.
Does Trident Lifeline Ltd pay dividends?
Trident Lifeline Ltd has a dividend yield of 0.12%.
What is the Return on Equity (ROE) of Trident Lifeline Ltd?
Trident Lifeline Ltd reported a return on equity of 22.60%. Its debt-to-equity ratio is 0.73.

Company Information

Incorporated in 2014, Trident Lifeline Ltd manufactures and sells pharmaceuticals products

Website tridentlifeline.com
Listed 10 Oct 2022
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/543616.md for Trident Lifeline Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month